The effect of treatment with 17 alpha-hydroxyprogesterone caproate on changes in cervical length over time.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 19716117.
- Also identified by DOI 10.1016/j.ajog.2009.07.009 and PMC identifier 3808191.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The purpose of this study was to examine whether women who were treated with 17 alpha-hydroxyprogesterone caproate (17-OHPC) to prevent recurrent preterm birth experienced a change in cervical shortening over time, compared with women who were not treated. We conducted a retrospective exposure cohort study of women who were enrolled in a prematurity prevention clinic from 1999-2008 with a singleton pregnancy with > or =1 previous spontaneous preterm births (<37 weeks of gestation) who underwent > or =2 cervical length measurements by endovaginal ultrasound. Of 200 women, 105 women received treatment with 17-OHPC; 95 women did not. Women who were treated with 17-OHPC were more likely to have experienced a previous preterm birth (26.0 vs 27.8 weeks; P = .01) than those who were not treated with 17-OHPC. There was no difference in the average weekly change in cervical length among women treated with 17-OHPC, compared with those who were not, after adjustment for covariates (0.79 mm/week; 95% confidence interval, -1.18 to 2.76). There was no difference in the average weekly change in cervical length measurements over time in women who underwent 17-OHPC treatment, compared with those who were not treated.
Medical subject headings
- Cervix Uteri
- Hydroxyprogesterones
- Progestins